198 related articles for article (PubMed ID: 556571)
1. Interaction of zymosan and of activated properdin with factor D-depleted guinea pig serum: implications for the mechanism of initial C3 cleavage via the alternative complement pathway.
Brade V; Bentley C; Bitter-Suermann D; Hadding U
Z Immunitatsforsch Immunobiol; 1977 Feb; 152(5):402-14. PubMed ID: 556571
[TBL] [Abstract][Full Text] [Related]
2. Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.
Vogt W; Schmidt G; Lynen R; Dieminger L
J Immunol; 1975 Feb; 114(2 Pt 1):671-7. PubMed ID: 804510
[TBL] [Abstract][Full Text] [Related]
3. Isolation and characterization of Guinea pig properidin.
Nicholson A; Austen KF
J Immunol; 1977 Jan; 118(1):103-8. PubMed ID: 830742
[TBL] [Abstract][Full Text] [Related]
4. Activation of factor B and C3 in guinea pig serum by zymosan or by activated properdin depends on the presence of factor D.
Brade V; Bentley C; Kossorotow A; Bitter-Suermann D
Monogr Allergy; 1977; 12():83-5. PubMed ID: 917024
[No Abstract] [Full Text] [Related]
5. Formation and composition of the C3 activating enzyme complex of the properdin system. Sequential assembly of its components on solid-phase trypsin-agarose.
Vogt W; Schmidt G; Dieminger L; Lynen R
Z Immunitatsforsch Exp Klin Immunol; 1975 Jul; 149(5):440-55. PubMed ID: 126576
[TBL] [Abstract][Full Text] [Related]
6. Hypocomplementemia of membranoproliferative nephritis. Dependence of the nephritic factor reaction on properdin factor B.
Ruley EJ; Forristal J; Davis NC; Andres C; West CD
J Clin Invest; 1973 Apr; 52(4):896-904. PubMed ID: 4693654
[TBL] [Abstract][Full Text] [Related]
7. Interaction of C3b, B, and D in the alternative pathway of complement activation.
Nicholson A; Brade V; Schorlemmer HU; Burger R; Bitter-Suermann D; Hadding U
J Immunol; 1975 Oct; 115(4):1108-13. PubMed ID: 240884
[TBL] [Abstract][Full Text] [Related]
8. The reaction of zymosan with the properdin system in normal and C4-deficienct guinea pig serum. Demonstration of C3- and C5-cleaving multi-unit enzymes, both containing factor B, and acceleration of their formation by the classical complement pathway.
Brade V; Lee GD; Nicholson A; Shin HS; Mayer MM
J Immunol; 1973 Nov; 111(5):1389-400. PubMed ID: 4795621
[No Abstract] [Full Text] [Related]
9. The rabbit properdin system: I. Identification of a new factor and purification of rabbit properdin.
Naff GB; Hedrick SW; Ratnoff WD; Novak MA; Smith MC; Steiner C; Todd EW
J Immunol; 1980 Jun; 124(6):2625-31. PubMed ID: 6900053
[TBL] [Abstract][Full Text] [Related]
10. Complement activation in semisolid media: insolubilization of alternative pathway convertases in agar gels with C3 nephritic factor-containing sera.
Arnaout MA; Davis AE; Rosen RS; Alper CA
J Immunol; 1977 Oct; 119(4):1316-20. PubMed ID: 894039
[TBL] [Abstract][Full Text] [Related]
11. Formation of the C3-cleaving properdin enzyme on zymosan. Demonstration that factor D is replaceable by proteolytic enzymes.
Brade V; Nicholson A; Bitter-Suermann D; Hadding U
J Immunol; 1974 Dec; 113(6):1735-43. PubMed ID: 4279261
[No Abstract] [Full Text] [Related]
12. Complement activation in semi-solid medium: Insolubilization of properdin and the third component of complement (C3) in agar gels.
Ziegler JB; Watson L; Goodkofsky I; Alper CA; Lepow IH
J Immunol; 1976 Jan; 116(1):75-9. PubMed ID: 812917
[TBL] [Abstract][Full Text] [Related]
13. A properdin system intermediate formed by zymosan and serum at 0 degrees C.
Yukiyama Y; Lew FT; Waks HS; Osler AG
J Immunol; 1976 Jan; 116(1):188-93. PubMed ID: 812914
[TBL] [Abstract][Full Text] [Related]
14. Activation of the alternative pathway of complement in childhood acute lymphoblastic leukemia.
Kalwinsky DK; Urmson JR; Stitzel AE; Spitzer RE
J Lab Clin Med; 1976 Nov; 88(5):745-56. PubMed ID: 1068203
[TBL] [Abstract][Full Text] [Related]
15. Alternative pathway of complement: nonenzymatic, reversible transition of precursor to active properdin.
Götze O; Medicus RG; Müller-Eberhard HJ
J Immunol; 1977 Feb; 118(2):525-32. PubMed ID: 839069
[TBL] [Abstract][Full Text] [Related]
16. Covalent linkage of C3 to properdin during complement activation.
Whiteman LY; Purkall DB; Ruddy S
Eur J Immunol; 1995 May; 25(5):1481-4. PubMed ID: 7774654
[TBL] [Abstract][Full Text] [Related]
17. Assembly of the membrane attack complex promotes decay of the alternative pathway C3 convertase on Neisseria gonorrhoeae.
Densen P; McRill CM; Ross SC
J Immunol; 1988 Dec; 141(11):3902-9. PubMed ID: 3141507
[TBL] [Abstract][Full Text] [Related]
18. Formation in the presence of C3 nephritic factor (C3NeF) of an alternative pathway C3 convertase containing uncleaved B.
Daha MR; Fearon DT; Austen KF
Immunology; 1976 Nov; 31(5):789-96. PubMed ID: 992711
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of activation of the properdin system. Studies on properdin electrophoretic mobility in agarose activation of the alternative pathway.
Adam C; Williams DG; Peters DK
Clin Exp Immunol; 1975 Nov; 22(2):240-8. PubMed ID: 813932
[TBL] [Abstract][Full Text] [Related]
20. A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells.
Schwendinger MG; Spruth M; Schoch J; Dierich MP; Prodinger WM
J Immunol; 1997 Jun; 158(11):5455-63. PubMed ID: 9164968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
